Research Article
Elevated Soluble Galectin-3 as a Marker of Chemotherapy Efficacy in Breast Cancer Patients: A Prospective Study
Table 2
Plasma Gal-3 level distribution in study population.
| Plasma Gal-3 levels in study population | | Mean | Range (CI 95%) |
| Nontumoral controls | 10.2 | 8.92-11.5 | Adjuvant group | Presurgery | 12.8 | 10.7-14.9 | Postsurgery | 11.8 | 9.3-14.2 | CTX-1 | 18.7 | 15.7- 21.7 | CTX-2 | 29.0 | 23.6-34.5 | CTX-3 | 36.3 | 30.6-42.0 | CTX-4 | 19.3 | 13.9-24.6 | Neoadjuvant group | Prechemotherapy | 8.47 | 5.6-11.3 | CTX-1 | 10.86 | 7.9-13.7 | CTX-2 | 9.62 | 7.6-11.6 | CTX-3 | 10.38 | 7.9-12.9 | CTX-4 | 10.90 | 8.42-13.4 |
|
|
CI: confidence interval; CTX: chemotherapy.
|